FDA clears first-ever blood test to aid Alzheimer’s diagnosis, paving way for global rollout

A groundbreaking blood test designed to aid in the diagnosis of Alzheimer’s disease is set to become available in the United States by late June, marking a major milestone in the global fight against dementia. The Japanese diagnostics company behind the innovation, Fujirebio Holdings Inc., announced the launch following regulatory clearance from the U.S. Food and Drug Administration (FDA) last week.

Faster, cheaper, and less invasive

The new test, which can detect amyloid proteins—key indicators of Alzheimer’s—in a patient’s blood, offers a dramatically less invasive and more affordable alternative to traditional diagnostic methods. Current standards often involve costly PET scans or spinal fluid analysis, procedures that can be uncomfortable, time-consuming, and financially burdensome.

The new test promises a much quicker process. “The process, which takes roughly 30 minutes from drawing the blood to diagnosis, will be available to patients at a fraction of the cost of a PET scan,” Fujirebio’s president Goki Ishikawa, confirmed in an interview Tuesday.

Want an SUV with Easy Access and Comfort for Seniors? Here’s How to Get It!

want an suv with easy access and comfort for seniors? here’s how to get it!...

May 21, 2025

12:33 pm

Drive into the Future with the 2025 Subaru Forester

drive into the future with the 2025 subaru forester...

May 21, 2025

12:23 pm

Explore Surprisingly Affordable Luxury RAM 1500

explore surprisingly affordable luxury ram 1500...

May 21, 2025

12:33 pm

Explore The 2025 Jeep Compas: Adventure Awaits!

explore the 2025 jeep compas: adventure awaits!...

May 21, 2025

12:35 pm

The test has been approved for individuals aged 55 and older who are already showing signs of cognitive decline. Experts believe this will play a crucial role in identifying patients earlier and expanding access to new treatments.

First phase launch in the U.S.

According to Ishikawa, the blood test will initially be introduced at around 50 research institutes and hospitals across the U.S. that specialize in Alzheimer’s care. Fujirebio is collaborating with industry giants like Beckman Coulter Inc. to scale up production and expand market reach.

“The FDA’s clearance is a significant step forward,” said Ishikawa. “We’re working with partners to ensure this technology reaches as many patients as possible.”

2025 Jeep Wrangler Price One Might Not Want to Miss!

2025 jeep wrangler price one might not want to miss!...

May 21, 2025

12:30 pm

Celebrate the Holidays in a New Hyundai Palisade

celebrate the holidays in a new hyundai palisade...

May 21, 2025

12:17 pm

Need a new Car? Rent To Own Cars No Credit Check

need a new car? rent to own cars no credit check ...

May 21, 2025

12:38 pm

Want an SUV with Easy Access and Comfort for Seniors? Here’s How to Get It!

want an suv with easy access and comfort for seniors? here’s how to get it!...

May 21, 2025

12:16 pm

Global ambitions on the horizon

Fujirebio’s ambitions extend well beyond U.S. borders. The company is preparing regulatory filings in Japan as early as August, and aims to seek approval in Europe before the end of the year. China could follow in 2026, with Fujirebio’s partner there expected to submit data next year. Meanwhile, Agappe Diagnostics Ltd., Fujirebio’s Indian partner, has already filed for approval with Indian regulators.

“We have a presence in Japan but that’s not necessarily the case in markets overseas,” Ishikawa explained. “We can’t get the market shares by ourselves, but if we supply the raw materials to partners, we can benefit through them.”

Unlocking the future of Alzheimer’s care

With nearly 7 million Americans currently living with Alzheimer’s disease—and millions more worldwide—the approval and imminent rollout of this blood test could mark a turning point. Quicker, cheaper, and more accessible diagnostics will not only help identify the disease earlier but could also accelerate the use of new drugs like Leqembi (by Eisai and Biogen) and Kisunla (by Eli Lilly), which have faced hurdles due to the lack of scalable diagnostic tools.

Experts say this innovation may finally bring Alzheimer’s care into a new era—one where early detection and timely intervention become the norm, not the exception.

This article First-ever Alzheimer’s blood test to launch in U.S. by June appeared first on BreezyScroll.

Read more on BreezyScroll.